Lung cancer small cell normally is classified as limited or extensive. Usually, this type of lung cancer has already spread by the time they are diagnosed although it is not evident by x-ray, so it is expected that the SCLC can not be cured with surgery alone.
Limited Stage
The most commonly used treatment for limited stage SCLC is a combination of two or more chemotherapy drugs, usually cisplatin or carboplatin combined with etoposide, usually administered for approximately six months. It is possible that the addition of topotecan or paclitaxel improves survival. For the small cell cancer with probability of cure, it is often recommended additional thoracic radiotherapy to chemotherapy, particularly because SCLC tends to be hili, ie not to be peripheral, concentrated in the center of the chest. is expected to occur more side effects with combination therapy, such as difficulty breathing and swallowing.
Thoracic radiotherapy was not performed in patients suffering from a severe lung disease and other disorders in addition to severe lung cancer. Sometimes, if the SCLC is highly localized, the cancer is removed through surgery and then administered a combination of adjuvant chemotherapy (poliquimioterpia). If he is treated with chemotherapy with or without radiotherapy, it is possible that the decrease in tumor size and start a referral. However, eventually the cancer will come back to grow again.
The SCLC commonly spreads to the brain, including in patients who received thoracic radiotherapy. For this reason, if there is a good response to initial treatment, may be administered for prophylactic cranial irradiation reduce the risk of brain metastases, also increased the likelihood of increased survival. The administration of pre-radiation of the brain has resulted in benefits in overall survival, according to a recent review of studies collected. Expected side effects as memory loss and clumsiness, with cranial radiation as a direct result of radiation.
The survival rate of the first year for people with limited stage SCLC treated with chemotherapy and radiation (this is the most favorable group) is 60 . Within two years the rate drops to 30 , and 5 year olds decreased from 10 to 15 . Due to the lack of success, doctors are studying other methods to treat these cancers. Clinical trials of new chemotherapy drugs or other treatments such as gene therapy or immunotherapy, are a worthwhile option and can benefit both the patient and future patients.
Advanced or disseminated
SCLC in the advanced stage can be managed quimioterapia'normalmente with carboplatin or cisplatin with etoposido'permitiendo extend the patient's life expectancy by 70 to 80 . Eventually, the cancer becomes resistant to treatment, requiring the use other medicines. Radiation therapy can control the symptoms of growth within the lung or spread to the bones and brain. Sometimes pre-treated with radiation to the brain.
Approximately 20 to 30 of people living in advanced stage SCLC live 1 year. Within two years, only 5 remain alive. And only 1 to 2 of people with advanced-stage SCLC survive five years after detection of cancer. If the patient is too sick to tolerate the chemotherapy, the best plan is to provide palliative care: pain relief of respiratory problems and other symptoms. Although suffering from an incurable lung cancer patients should seek to maximize their life, should enjoy every day. This means you must be as symptom free as possible. In cases of lung cancer in advanced stage the main problem may be the pain. The growth of the cancer around certain nerves may cause an intense pain. However, this pain can be alleviated with medication. Radiotherapy can also be useful. May wish to participate in clinical trials of new chemotherapy drugs or other treatments such as antiangiogenic therapy, immunotherapy or gene therapy.
| Related Products | |||||
|---|---|---|---|---|---|
| | | |||
| Surviving Mesothelioma and Other Cancers: A Patient's Guide by Paul Kraus (Paperback - Oct 10, 2005) | Malignant Mesothelioma: Pathogenesis, Diagnosis, and Translational Therapies by Harvey I. Pass, Nicholas Vogelzang, and Michele Carbone (Hardcover - Jun 14, 2005) | Malignant Mesothelioma by Douglas W Henderson (Library Binding - Oct 1, 1991) | |||
